Unknown

Dataset Information

0

Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.


ABSTRACT: The serotonin transporter (SERT) is the primary target for antidepressant drugs. The existence of a high affinity primary orthosteric binding site (S1) and a low affinity secondary site (S2) has been described, and their relation to antidepressant pharmacology has been debated. Herein, structural modifications to the N, 4, 5, and 4' positions of (±)citalopram (1) are reported. All of the analogues were SERT-selective and demonstrated that steric bulk was tolerated at the SERT S1 site, including two dimeric ligands (15 and 51). In addition, eight analogues were identified with similar potencies to S-1 for decreasing the dissociation of [(3)H]S-1 from the S1 site via allosteric modulation at S2. Both dimeric compounds had similar affinities for the SERT S1 site (Ki = 19.7 and 30.2 nM, respectively), whereas only the N-substituted analogue, 51, was as effective as S-1 in allosterically modulating the binding of [(3)H]S-1 via S2.

SUBMITTER: Banala AK 

PROVIDER: S-EPMC3894853 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.

Banala Ashwini K AK   Zhang Peng P   Plenge Per P   Cyriac George G   Kopajtic Theresa T   Katz Jonathan L JL   Loland Claus Juul CJ   Newman Amy Hauck AH  

Journal of medicinal chemistry 20131202 23


The serotonin transporter (SERT) is the primary target for antidepressant drugs. The existence of a high affinity primary orthosteric binding site (S1) and a low affinity secondary site (S2) has been described, and their relation to antidepressant pharmacology has been debated. Herein, structural modifications to the N, 4, 5, and 4' positions of (±)citalopram (1) are reported. All of the analogues were SERT-selective and demonstrated that steric bulk was tolerated at the SERT S1 site, including  ...[more]

Similar Datasets

| S-EPMC2932959 | biostudies-literature
| PRJNA1152286 | ENA
| S-EPMC3990943 | biostudies-literature
| S-EPMC6521218 | biostudies-literature
| S-EPMC2045233 | biostudies-literature
| S-EPMC2951635 | biostudies-literature
| S-EPMC7110993 | biostudies-literature
| S-EPMC7241555 | biostudies-literature
| S-EPMC6200329 | biostudies-literature
| S-EPMC10338411 | biostudies-literature